232 related articles for article (PubMed ID: 34007062)
21. Δ
Darmani NA; Belkacemi L; Zhong W
Eur J Pharmacol; 2019 Dec; 865():172806. PubMed ID: 31738934
[TBL] [Abstract][Full Text] [Related]
22. Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication.
Balster RL; Prescott WR
Neurosci Biobehav Rev; 1992; 16(1):55-62. PubMed ID: 1313164
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice.
Darmani NA
Pharmacol Biochem Behav; 2001 Feb; 68(2):311-7. PubMed ID: 11267636
[TBL] [Abstract][Full Text] [Related]
24. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
25. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea.
Parker LA; Mechoulam R; Schlievert C; Abbott L; Fudge ML; Burton P
Psychopharmacology (Berl); 2003 Mar; 166(2):156-62. PubMed ID: 12528012
[TBL] [Abstract][Full Text] [Related]
26. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.
Hoffman AF; Oz M; Yang R; Lichtman AH; Lupica CR
Learn Mem; 2007; 14(1-2):63-74. PubMed ID: 17202425
[TBL] [Abstract][Full Text] [Related]
27. The extracellular regulated kinases (ERK) 1/2 mediate cannabinoid-induced inhibition of gap junctional communication in endothelial cells.
Brandes RP; Popp R; Ott G; Bredenkötter D; Wallner C; Busse R; Fleming I
Br J Pharmacol; 2002 Jul; 136(5):709-16. PubMed ID: 12086980
[TBL] [Abstract][Full Text] [Related]
28. [Cannabis and cannabinoids as drugs].
Khiabani HZ; Mørland J
Tidsskr Nor Laegeforen; 2007 Mar; 127(5):579-82. PubMed ID: 17332810
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological evaluation of aerosolized cannabinoids in mice.
Lichtman AH; Peart J; Poklis JL; Bridgen DT; Razdan RK; Wilson DM; Poklis A; Meng Y; Byron PR; Martin BR
Eur J Pharmacol; 2000 Jul; 399(2-3):141-9. PubMed ID: 10884513
[TBL] [Abstract][Full Text] [Related]
30. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
31. Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats.
Wiley JL; Lefever TW; Cortes RA; Marusich JA
Pharmacol Biochem Behav; 2014 Sep; 124():123-8. PubMed ID: 24887450
[TBL] [Abstract][Full Text] [Related]
32. Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer.
Zaytseva YY; Elliott VA; Rychahou P; Mustain WC; Kim JT; Valentino J; Gao T; O'Connor KL; Neltner JM; Lee EY; Weiss HL; Evers BM
Carcinogenesis; 2014 Jun; 35(6):1341-51. PubMed ID: 24510238
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.
Tacconi C; Correale C; Gandelli A; Spinelli A; Dejana E; D'Alessio S; Danese S
Gastroenterology; 2015 Jun; 148(7):1438-51.e8. PubMed ID: 25754161
[TBL] [Abstract][Full Text] [Related]
34. Δ
Shum C; Dutan L; Annuario E; Warre-Cornish K; Taylor SE; Taylor RD; Andreae LC; Buckley NJ; Price J; Bhattacharyya S; Srivastava DP
Mol Cell Neurosci; 2020 Mar; 103():103463. PubMed ID: 31917333
[TBL] [Abstract][Full Text] [Related]
35. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor.
Hart S; Fischer OM; Ullrich A
Cancer Res; 2004 Mar; 64(6):1943-50. PubMed ID: 15026328
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and pharmacodynamics of cannabinoids.
Grotenhermen F
Clin Pharmacokinet; 2003; 42(4):327-60. PubMed ID: 12648025
[TBL] [Abstract][Full Text] [Related]
37. [Drug discrimination properties and cytotoxicity of the cannabinoid receptor ligands].
Tomiyama K; Funada M
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2012 Jun; 47(3):135-43. PubMed ID: 22894054
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-17~92 inhibits colorectal cancer progression by targeting angiogenesis.
Ma H; Pan JS; Jin LX; Wu J; Ren YD; Chen P; Xiao C; Han J
Cancer Lett; 2016 Jul; 376(2):293-302. PubMed ID: 27080303
[TBL] [Abstract][Full Text] [Related]
39. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
40. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.
Recht LD; Salmonsen R; Rosetti R; Jang T; Pipia G; Kubiatowski T; Karim P; Ross AH; Zurier R; Litofsky NS; Burstein S
Biochem Pharmacol; 2001 Sep; 62(6):755-63. PubMed ID: 11551521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
